P06276 |
CHLE_HUMAN |
Pain [ICD-11: MG30-MG3Z] |
P06276 |
CHLE_HUMAN |
Tonus and reflex abnormality [ICD-11: MB47] |
P06276 |
CHLE_HUMAN |
Alzheimer disease [ICD-11: 8A20] |
P06276 |
CHLE_HUMAN |
Mild neurocognitive disorder [ICD-11: 6D71] |
P06276 |
CHLE_HUMAN |
Eexposure to noxious substances harmful effect [ICD-11: NE61] |
P06276 |
CHLE_HUMAN |
Toxicity [ICD-11: N.A.] |
P06276 |
CHLE_HUMAN |
Unspecific substance harmful effect [ICD-11: NE6Z] |
P22303 |
ACES_HUMAN |
Alzheimer disease [ICD-11: 8A20] |
P22303 |
ACES_HUMAN |
Glaucoma [ICD-11: 9C61] |
P22303 |
ACES_HUMAN |
Myasthenia gravis [ICD-11: 8C6Y] |
P22303 |
ACES_HUMAN |
Oesophageal/gastroduodenal disorder [ICD-11: DD90] |
P22303 |
ACES_HUMAN |
Pediculosis [ICD-11: 1G00] |
P22303 |
ACES_HUMAN |
Unspecific substance harmful effect [ICD-11: NE6Z] |
P22303 |
ACES_HUMAN |
Mild neurocognitive disorder [ICD-11: 6D71] |
P22303 |
ACES_HUMAN |
Parasitic worm infestation [ICD-11: 1F90] |
P22303 |
ACES_HUMAN |
Dementia [ICD-11: 6D80-6D8Z] |
P22303 |
ACES_HUMAN |
Pain [ICD-11: MG30-MG3Z] |
P22303 |
ACES_HUMAN |
Parkinsonism [ICD-11: 8A00] |
P22303 |
ACES_HUMAN |
Substance abuse [ICD-11: 6C40] |
P22303 |
ACES_HUMAN |
Lips/oral mucosa miscellaneous disorder [ICD-11: DA02] |
P22303 |
ACES_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P22303 |
ACES_HUMAN |
Urinary system disease [ICD-11: GC2Z] |
P22303 |
ACES_HUMAN |
Neurodegenerative disorder [ICD-11: 8A20-8A23] |
P15121 |
ALDR_HUMAN |
Neuropathy [ICD-11: 8C0Z] |
P15121 |
ALDR_HUMAN |
Pain [ICD-11: MG30-MG3Z] |
P15121 |
ALDR_HUMAN |
Rheumatoid arthritis [ICD-11: FA20] |
P15121 |
ALDR_HUMAN |
Acute diabete complication [ICD-11: 5A2Y] |
P15121 |
ALDR_HUMAN |
Thrombosis [ICD-11: DB61-GB90] |
P15121 |
ALDR_HUMAN |
Cataract [ICD-11: 9B10] |
P15121 |
ALDR_HUMAN |
Glaucoma [ICD-11: 9C61] |
P15121 |
ALDR_HUMAN |
Schizophrenia [ICD-11: 6A20] |
P15121 |
ALDR_HUMAN |
Gout [ICD-11: FA25] |
P15121 |
ALDR_HUMAN |
Head and neck cancer [ICD-11: 2D42] |